Evaluation of platelet parameters in healthy apheresis donors using the ADVIA 120™

Apheresis donors and platelet function: inherent platelet responsiveness influences platelet quality

“…Reports that donors have reduced mean PLT volumes after apheresis, however, and that harvested PLTs have an increased proportion of large PLTs support the view that apheresis preferentially removes larger, and potentially more responsive, PLTs. 20,38 The pattern of apheresis-induced changes in PLT responsiveness is clearly complex; the impaired response described by Choi 22 varied between individuals, and most notably between agonists, with responses to epinephrine being most affected.…”

“…In essence, are PLT concentrates produced from donors whose PLTs respond more readily more likely to be activated? Conversely the effect of the donation process on the donors' remaining circulating PLTs remains inconclusive, with some authors finding little evidence of activation or of change in agonist response, 20,21 whereas others have reported reduced responses to agonists resulting from the apheresis procedure. 22,23 We have addressed these donor-related variables in a cohort of 506 regular blood donors whose in vitro PLT response through the ADP and collagen signaling pathways had been previously analyzed by flow cytometry.…”

Factors related to low serum vitamin B12 levels in elderly patients with non‐atrophic gastritis in contrast to patients with normal vitamin B12 levels

“…In malignant diseases, such as breast cancer, ovarian and colorectal cancers, PLR is assumed as a sensitive marker for prognostic evaluation . In clinical practice, there are some easily measurable parameters in complete blood count, such as MPV, and MPV projects the average size of platelets and platelet production rate . There is abundant evidence that MPV levels increase in malignant, inflammatory and infectious conditions, such as gastric carcinoma, celiac disease and ulcerative colitis .…”

Postdonation platelet counts are safe when collecting platelets with the Trima Accel using a postdonation platelet count target of ≥50,000 platelets/μL

“…It was concluded that plateletpheresis, when carried out on healthy donors, does not result in clinical problems. Ifran et al also concluded that although a decrease in postdonation platelet count was seen, no other remarkable changes in donor parameters occurs [3]. Akay et al studied the effects of plateletpheresis on donor platelet function and coagulation [4].…”